Literature DB >> 23867717

Clinical and morphological evaluation of gold micro shunt after unsuccessful surgical treatment of patients with primary open-angle glaucoma.

M Rękas1, B Pawlik, B Grala, W Kozłowski.   

Abstract

PURPOSE: To report the clinicopathologic features in a series of patients after ineffective glaucoma surgery with gold micro shunts (GMS) 2 years after the procedure.
METHODS: This was an interventional case series study including two cases of GMS and two of GMS+ removal. Each specimen was sectioned into three portions: proximal, middle, and distal, and embedded into paraffin blocks, cut into 3 μm sections and stained with hematoxylin and eosin and Masson's trichrome. In the case of inflammatory infiltrations a reaction with an LCA (CD45) monoclonal antibody was performed.
RESULTS: Mean IOP before GMS removal was 28.8 ± 4.3 mm Hg, and the patients were administered 2.3 ± 0.5 anti-glaucoma drugs. The progression of changes in the visual field was observed in all cases. In three cases different grade intensification of corneal decompression was observed. Colonization of the connective tissue was found in the channels and around the microimplant in all cases. In two cases infiltration was detected from giant polynuclear and mononuclear cells.
CONCLUSIONS: Connective tissue colonization was the cause of GMS obstruction. This can be a non-inflammatory process, but it may also result from chronic inflammation occurring in the suprachoroidal space.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23867717      PMCID: PMC3806560          DOI: 10.1038/eye.2013.154

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


Introduction

Hydrostatic pressure difference between the anterior chamber and the suprachoroidal space is the basis for surgical use of the unconventional outflow pathway.[1] Implants enhancing the unconventional outflow pathway have already undergone specific evolution through GMS (SOLX Inc., Occulogix, Waltham, MA, USA) used via an ab externo approach to CyPassMicro-Stent (Transcend Medical) the implantation of which is performed from the anterior chamber to the suprachoroidal space.[2, 3] However, it seems that the physiology of suprachoroidal space has not been well recognized yet as regards the possibility of IOP regulation and the reaction to the presence of a foreign body in the long-term follow-up.

Case reports

There were four patients aged 70.2±15.5 years with POAG. Mean IOP before GMS implantation was 22.5±3.5 mm Hg, and the patients used 2.5±0.6 (median: Me−2.5) medications. The mean IOP before GMS removal was 28.8±4.3 mm Hg (P=0.002), and the patients used 2.3±0.5 (Me−2.0) medications (P=0.361). The mean time for the implant removal was 29.8±8.3 months.

Case 1

A 90-year-old man with GMS removed from the right eye 29 months after implantation. IOP was 25.0 mm Hg (Ganfort), and progression in the visual field was observed (MD=−17.91). The central corneal thickness (CCT) increased from 480 to 568 μm and the corneal decompensation was detected despite the lack of GMS contact with the endothelium (OCT Visante). In the middle portion of GMS the presence of collagen-rich connective capsule-like reaction about 100-μm thick was found (Figure 1). The presence of cell-rich collagen-poor connective tissue was also found between the plates. There were also observed chronic inflammatory infiltration cells, polynuclear giant cells, and small blood vessels (Figure 2a).
Figure 1

Macroscopic image of the removed microimplant (case 1). Colonization of the connective tissue around the microimplant. (a) Proximal portion; fragments of the connective tissue at the side of the sclera, (b–d) distal portion: connective tissue (at the choroidal side) blocking the channels of the microimplant (Cannon EF 100 mm f/2.8 L Macro IS USM).

Figure 2

Microphotograph of the removed microimplant. (a) Case 1: in the middle portion the implant is surrounded by collagen-rich connective tissue capsule. A cluster of polynuclear giant cells present between the implant plates (asterisk). On the left side the giant cells combine with collagen-poor granulation tissue with numerous small blood vessels filling the remaining part of the microimplant channel. Below, within the sclera, is shown a visible focus of dispersed inflammatory infiltration (arrow) (H&E × 200). (b) Case 3: amorphous thickened protein masses between microimplant plates (H&E × 200). (c) Case 4: inflammatory infiltrations from lymphocytic cells between the GMS plates (H&E × 400). (d) Case 4: the membrane expression of LCA (CD45) in the infiltration from mononuclear cells (immunohistochemical staining with a anti-LCA antibody × 400).

Case 2

In the case of a 69-year-old woman GMS+ was removed from the left eye 21 months after surgery. Before removal, IOP was 24.0 mm Hg (Xalacom). Progression in the visual field (MD=−8.55) and corneal decompensation were observed. CCT increased from 534 to 676 μm despite the lack of GMS contact with the endothelium. In the middle portion of GMS the presence of collagen-rich connective capsule-like reaction was detected, but the capsule was thin (about 50 μm). In case no. 2 the presence of cell-rich collagen-poor connective tissue was found between the plates.

Case 3

The cause of GMS removal from a right eye of a 70-year-old man was the decrease of endothelium from 2579 to 1685 cells mm−2 despite the lack of contact with GMS, and progression in the visual field was observed (MD=−3.49). IOP was 22.0 mm Hg (Ganfort) 28 months after the surgery. In the middle and distal part the GMS was surrounded by collagen-rich connective tissue capsule. The proximal, middle and distal portion channels were partially filled with dense amorphous protein masses (Figure 2b).

Case 4

In a 52-year-old man, 41 months after primary surgery, GMS+ was removed from the right eye because of the lack of IOP control despite of the maximal antiglaucoma therapy (Duotrav, Azopt). There were observed an increase of IOP to 41.0 mm Hg and progression in the visual field (MD=−4.23). No contact of the implant with the endothelium was observed. Collagen-rich connective tissue in the implant channels and dispersed chronic inflammatory infiltrations both around and inside the implant were detected. Lymphocytic infiltration (LCA+) was accompanied with clusters of numerous polynuclear giant cells (Figure 2c and d).

Discussion

GMS is one of the most modern implants improving the unconventional pathway outflow. Despite encouraging initial clinical reports, in the medium-term follow-up the IOP reduction decreased, whereas the number of applied anti-glaucoma medications increased.[4] It was suggested that the formation of a fibrotic capsule around the device was responsible for the failure of the GMS surgery.[4, 5, 6] We found fibroblasts both around the microimplant and within GMS channels. Apart from connective tissue, amorphous masses were also found in the proximal portion of the microimplant. It cannot be excluded that due to nutritional disorders there came to the degeneration of collagenized connective tissue. The presence of giant cells both around and inside the microimplant may point to the role of activated monocytes and macrophages in the pathomechanism of the development of GMS obstruction. Distinct inflammatory infiltrations from mononuclear cells were also observed in the specimens. Their occurrence proves specific immune response to the antigen presented by macrophages. Summing up, it should be concluded that microimplant obstruction caused by the connective tissue proliferation is the cause of the failure of surgery with GMS. This process can be non-inflammatory, but it can also result from chronic inflammation in the suprachoroidal space.
  6 in total

Review 1.  Micro-invasive glaucoma surgery: current perspectives and future directions.

Authors:  Hady Saheb; Iqbal Ike K Ahmed
Journal:  Curr Opin Ophthalmol       Date:  2012-03       Impact factor: 3.761

2.  Efficacy and safety of gold micro shunt implantation to the supraciliary space in patients with glaucoma: a pilot study.

Authors:  Shlomo Melamed; Guy J Ben Simon; Modi Goldenfeld; Gabriel Simon
Journal:  Arch Ophthalmol       Date:  2009-03

3.  Supraciliary shunt in refractory glaucoma.

Authors:  Michele Figus; Stefano Lazzeri; Paolo Fogagnolo; Michele Iester; Paolo Martinelli; Marco Nardi
Journal:  Br J Ophthalmol       Date:  2011-08-26       Impact factor: 4.638

4.  Histological findings of failed gold micro shunts in primary open-angle glaucoma.

Authors:  Luca Agnifili; Ciro Costagliola; Michele Figus; Giovanna Iezzi; Adriano Piattelli; Paolo Carpineto; Rodolfo Mastropasqua; Marco Nardi; Leonardo Mastropasqua
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-23       Impact factor: 3.117

5.  Hydrostatic pressure of the suprachoroidal space.

Authors:  K Emi; J E Pederson; C B Toris
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-02       Impact factor: 4.799

6.  In vivo analysis of conjunctiva in gold micro shunt implantation for glaucoma.

Authors:  Leonardo Mastropasqua; Luca Agnifili; Marco Ciancaglini; Mario Nubile; Paolo Carpineto; Vincenzo Fasanella; Michele Figus; Stefano Lazzeri; Marco Nardi
Journal:  Br J Ophthalmol       Date:  2010-08-30       Impact factor: 4.638

  6 in total
  10 in total

1.  Safety and effectiveness of gold glaucoma micro shunt for reducing intraocular pressure in Japanese patients with open angle glaucoma.

Authors:  Masaki Tanito; Etsuo Chihara
Journal:  Jpn J Ophthalmol       Date:  2017-06-09       Impact factor: 2.447

2.  [STARflo-a suprachoroidal drainage implant in glaucoma surgery].

Authors:  S König; C W Hirneiß
Journal:  Ophthalmologe       Date:  2018-08       Impact factor: 1.059

3.  Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device.

Authors:  Marina Hovakimyan; Stefan Siewert; Wolfram Schmidt; Katrin Sternberg; Thomas Reske; Oliver Stachs; Rudolf Guthoff; Andreas Wree; Martin Witt; Klaus-Peter Schmitz; Reto Allemann
Journal:  Transl Vis Sci Technol       Date:  2015-06-30       Impact factor: 3.283

Review 4.  Suprachoroidal devices in glaucoma surgery.

Authors:  Jeffrey A Kammer; Kevin M Mundy
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Jan-Mar

5.  Gold shunt for refractory advanced low-tension glaucoma with spared central acuity.

Authors:  Ryan Le; Neeru Gupta
Journal:  Int Med Case Rep J       Date:  2016-03-18

6.  Comparing iStent versus CyPass with or without phacoemulsification in patients with glaucoma: a meta-analysis.

Authors:  Ali Mahdavi Fard; Leili Pourafkari; Sangita P Patel; Nader D Nader
Journal:  Ther Adv Chronic Dis       Date:  2019-08-01       Impact factor: 5.091

Review 7.  Translating Minimally Invasive Glaucoma Surgery Devices.

Authors:  Richard M H Lee; Yann Bouremel; Ian Eames; Steve Brocchini; Peng Tee Khaw
Journal:  Clin Transl Sci       Date:  2019-09-30       Impact factor: 4.689

8.  Subconjunctival bevacizumab to augment trabeculectomy with mitomycin C in the management of failed glaucoma surgery.

Authors:  Ahmed M Saeed; Tarek Tawfeek AboulNasr
Journal:  Clin Ophthalmol       Date:  2014-09-15

9.  Long-term Follow-up of a Case of Gold Shunt Surgery for Refractory Silicone Oil-induced Glaucoma.

Authors:  Ryan Le; Alan R Berger; Neeru Gupta
Journal:  J Glaucoma       Date:  2016-08       Impact factor: 2.503

Review 10.  Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions.

Authors:  Inês C F Pereira; Rosanne van de Wijdeven; Hans M Wyss; Henny J M Beckers; Jaap M J den Toonder
Journal:  Eye (Lond)       Date:  2021-06-14       Impact factor: 3.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.